Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Shares Issued (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Shares Issued for 5 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 175.78% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.3 million, a 2022.64% increase, with the full-year FY2024 number at $7.5 million, up 87.5% from a year prior.
  • Shares Issued was $2.4 million for Q3 2025 at Vivos Therapeutics, down from $3.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $8.0 million in Q1 2023 to a low of -$4.0 million in Q4 2023.
  • A 4-year average of $1.8 million and a median of $3.0 million in 2024 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 187.5% in 2024; the steepest drop was 50.74% in 2024.
  • Vivos Therapeutics' Shares Issued stood at $330000.0 in 2021, then tumbled by 1312.12% to -$4.0 million in 2023, then skyrocketed by 187.5% to $3.5 million in 2024, then plummeted by 30.63% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Shares Issued are $2.4 million (Q3 2025), $3.5 million (Q4 2024), and -$3.2 million (Q3 2024).